Menu

Researchers Succeed in Keeping Disembodied Pig Brains Alive

The organs showed neural activity for up to 36 hours, adding fuel to discussions about the ethics of future neuroscientific research.

May 1, 2018
Catherine Offord

FLICKR, NICK SALTMARSHA team of US researchers has kept disembodied pig brains alive in a comatose-like state for up to 36 hours, according to a report published last week (April 25) by MIT Technology Review. First revealed by Yale University neuroscientist Nenad Sestan at a meeting held on March 28 at the National Institutes of Health, the results have increased the urgency of the ethical debate surrounding the future of brain research.

Although other groups have managed to keep disembodied brainstems and hearts of rodents alive, the current project is noteworthy for the scale of the brain being preserved, and its apparent success. The results have yet to be published in a scientific journal.

The researchers achieved the feat by experimenting with more than 100 pig brains obtained from a slaughterhouse, Sestan disclosed at the meeting (via MIT Technology Review). While maintaining circulation to the organs with a setup of pumps and heated-up blood, the team observed normal-like patterns of cell activity, even though the brains were only attached to the setup several hours after the pigs were killed—meaning at least some cell death and damage to the organs would be likely.

“These brains may be damaged, but if the cells are alive, it’s a living organ,” Steve Hyman, director of psychiatric research at the Broad Institute in Cambridge, Massachusetts and one of the scientists briefed on the work, tells MIT Technology Review. “It’s at the extreme of technical know-how, but not that different from preserving a kidney.”

The reaction to the news has been mixed, The Guardian reports. Frances Edwards, a neuroscientist at University College London, notes that the technique could allow researchers to study animals’ neural networks in greater detail and develop better imaging techniques. But it’s unlikely to be replicated in humans, she adds.

“It would be a major, pretty much impossible step even to get this far with a human brain,” she tells The Guardian. “In the pig, you are taking a healthy animal and able to control exactly when and how it dies and immediately take out the brain.” In humans, instead, “by the time the brain is accessible it would be well and truly compromised.”

Nevertheless, several researchers argue that the time to consider the ethical implications of such research being carried out with human tissue is now, while brain preservation techniques, along with the development of brain surrogates such as chimaeras and brain organoids, are under development.

See “Human Brain Organoids Thrive in Mouse Brains

Writing last week (April 25) in Nature, Sestan, along with Hyman, biologist George Church, and 14 others, urged colleagues and the public to address questions such as “Who, if anyone, should ‘own’ ex vivo brain tissue, brain organoids or chimaeras?” and “Do ex vivo human brain models challenge our understanding of life and death?”

Neurobiologist Colin Blakemore of the School of Advance Study at the University of London tells BBC News that he seconds the authors’ message. “It is very, very important that there should be a public discussion about this,” he says, “not least because the researchers who have some investment can tell the public why it would be so important to develop such techniques.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.